BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 59 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q3 2023. The put-call ratio across all filers is 0.29 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,963 | -90.3% | 54,788 | 0.0% | 0.00% | – |
| Q2 2023 | $112,863 | -38.8% | 54,788 | -2.0% | 0.00% | – |
| Q1 2023 | $184,523 | +101.2% | 55,916 | 0.0% | 0.00% | – |
| Q4 2022 | $91,702 | -62.9% | 55,916 | 0.0% | 0.00% | – |
| Q3 2022 | $247,000 | +60.4% | 55,916 | 0.0% | 0.00% | – |
| Q2 2022 | $154,000 | -18.1% | 55,916 | 0.0% | 0.00% | – |
| Q1 2022 | $188,000 | -20.3% | 55,916 | -5.4% | 0.00% | – |
| Q4 2021 | $236,000 | +21.0% | 59,091 | 0.0% | 0.00% | – |
| Q3 2021 | $195,000 | +3.2% | 59,091 | +18.7% | 0.00% | – |
| Q2 2021 | $189,000 | -83.5% | 49,761 | -83.4% | 0.00% | – |
| Q1 2021 | $1,147,000 | -16.8% | 299,433 | -1.7% | 0.00% | – |
| Q4 2020 | $1,379,000 | -74.3% | 304,595 | -4.1% | 0.00% | -100.0% |
| Q3 2020 | $5,372,000 | +504.3% | 317,521 | +300.3% | 0.00% | – |
| Q2 2020 | $889,000 | +349.0% | 79,319 | +86.1% | 0.00% | – |
| Q1 2020 | $198,000 | +17.9% | 42,611 | +8.9% | 0.00% | – |
| Q4 2019 | $168,000 | +18.3% | 39,141 | +7.2% | 0.00% | – |
| Q3 2019 | $142,000 | -1.4% | 36,496 | 0.0% | 0.00% | – |
| Q2 2019 | $144,000 | -8.9% | 36,496 | 0.0% | 0.00% | – |
| Q1 2019 | $158,000 | +21.5% | 36,496 | 0.0% | 0.00% | – |
| Q4 2018 | $130,000 | -6.5% | 36,496 | 0.0% | 0.00% | – |
| Q3 2018 | $139,000 | -2.1% | 36,496 | 0.0% | 0.00% | – |
| Q2 2018 | $142,000 | +31.5% | 36,496 | +6.6% | 0.00% | – |
| Q1 2018 | $108,000 | -19.4% | 34,223 | 0.0% | 0.00% | – |
| Q4 2017 | $134,000 | -5.0% | 34,223 | 0.0% | 0.00% | – |
| Q3 2017 | $141,000 | -0.7% | 34,223 | 0.0% | 0.00% | – |
| Q2 2017 | $142,000 | -2.1% | 34,223 | 0.0% | 0.00% | – |
| Q1 2017 | $145,000 | +137.7% | 34,223 | +43.6% | 0.00% | – |
| Q4 2016 | $61,000 | +8.9% | 23,834 | +3.4% | 0.00% | – |
| Q3 2016 | $56,000 | 0.0% | 23,043 | 0.0% | 0.00% | – |
| Q2 2016 | $56,000 | -9.7% | 23,043 | 0.0% | 0.00% | – |
| Q1 2016 | $62,000 | -6.1% | 23,043 | 0.0% | 0.00% | – |
| Q4 2015 | $66,000 | +24.5% | 23,043 | 0.0% | 0.00% | – |
| Q3 2015 | $53,000 | -19.7% | 23,043 | +26.6% | 0.00% | – |
| Q2 2015 | $66,000 | -20.5% | 18,208 | -2.1% | 0.00% | – |
| Q1 2015 | $83,000 | – | 18,601 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Weaver Consulting Group | 130,000 | $437,000 | 0.21% |
| Ikarian Capital, LLC | 304,161 | $1,022,000 | 0.13% |
| ABNER HERRMAN & BROCK LLC | 265,000 | $890,000 | 0.12% |
| S.C. Financial Services, Inc. | 15,285 | $51,000 | 0.06% |
| JMAC ENTERPRISES LLC | 45,430 | $153,000 | 0.04% |
| CFO4Life Group, LLC | 12,000 | $40,000 | 0.01% |
| OSAIC HOLDINGS, INC. | 10,839 | $1,329,000 | 0.00% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 3,000 | $10,000 | 0.00% |
| BOOTHBAY FUND MANAGEMENT, LLC | 29,186 | $98,000 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 190,403 | $640,000 | 0.00% |